Meanwhile, another study used 11 EOC PDXs by transplanting tumor tissues orthotopically in the peritoneal cavity of nude mice to evaluate the activity of cediranib (a pan-VEGFR RTK inhibitor) alone or combined with chemotherapy, showing that different EOC PDX models displayed dissimilar response to cediranib, and that combination of cediranib and cisplatin increased the model mice survival and inhibited ascites and metastases while cediranib alone just exerted the decreasing effect on ascites but not on tumor dissemination in advanced EOC PDX 70. This evidence concerns the gene KDR and neoplasm.